Chao Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chao Yang has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Jihui Hao
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, China
12 shared publications - Jun Yu
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
11 shared publications - Tianxing Zhou
Pancreas Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
9 shared publications - Xiuchao Wang
Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
9 shared publications - Antao Chang
Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
8 shared publications - Tiansuo Zhao
Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
8 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 483
Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial
Gemcitabine resistance remains a major therapeutic barrier in pancreatic ductal adenocarcinoma (PDAC), for which median survival in advanced disease has remained near one year despite extensive clinical investigation. Using artificial intelligence (AI)-guided structure-based drug repurposing, we identified sitagliptin, a DPP-4 inhibitor for diabetes, as a candidate ribonucleotide reductase (RRM1/2) inhibitor that sensitizes PDAC to gemcitabine. Molecular dynamics simulations suggested that sitagliptin disrupts gemcitabine-RRM1/2 interactions, downregulating RRM1/2 expression and restoring chemosensitivity across PDAC cell lines, patient-derived organoids, and mouse models. Sitagliptin enhanced the anti-tumor efficacy of both gemcitabine-nab-paclitaxel (GnP) and FOLFIRINOX regimens in preclinical studies. We conducted SITGEM-CARE, a single-center phase 2 trial in 22 patients with locally advanced or metastatic PDAC (median age 65.0 years; ECOG performance status 1, 86.4%; Stage IV, 68.2%; liver metastases, 54.5%). Patients received sitagliptin 100 mg orally once daily continuously, plus gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m² on days 1 and 8 of 21-day cycles. Among 22 evaluable patients, eight achieved a partial response, and 11 had stable disease, yielding an objective response rate of 36.4% (95% CI: 17.2–59.3%) and a disease control rate of 86.4% (95% CI: 65.1–97.1%), with tumor shrinkage in 86.4% of patients. At a median follow-up of 9.9 months, the median progression-free survival was 6.6 months (95% CI: 4.8–12.4) with 6-month and 9-month PFS rates of 63.6% and 43.5%, respectively. Median overall survival was 12.5 months (95% CI: 7.8-not reached), with 62.9% of patients alive at 12 months. Furthermore, treatment was well tolerated, with no Grade 4/5 treatment-related adverse events. These findings are hypothesis-generating and warrant confirmation in adequately powered, randomized trials. ClinicalTrials.gov: NCT05947825.
- 3 November 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 483
Open AccessSitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial
Gemcitabine resistance remains a major therapeutic barrier in pancreatic ductal adenocarcinoma (PDAC), for which median survival in advanced disease has remained near one year despite extensive clinical investigation. Using artificial intelligence (AI)-guided structure-based drug repurposing, we identified sitagliptin, a DPP-4 inhibitor for diabetes, as a candidate ribonucleotide reductase (RRM1/2) inhibitor that sensitizes PDAC to gemcitabine. Molecular dynamics simulations suggested that sitagliptin disrupts gemcitabine-RRM1/2 interactions, downregulating RRM1/2 expression and restoring chemosensitivity across PDAC cell lines, patient-derived organoids, and mouse models. Sitagliptin enhanced the anti-tumor efficacy of both gemcitabine-nab-paclitaxel (GnP) and FOLFIRINOX regimens in preclinical studies. We conducted SITGEM-CARE, a single-center phase 2 trial in 22 patients with locally advanced or metastatic PDAC (median age 65.0 years; ECOG performance status 1, 86.4%; Stage IV, 68.2%; liver metastases, 54.5%). Patients received sitagliptin 100 mg orally once daily continuously, plus gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m² on days 1 and 8 of 21-day cycles. Among 22 evaluable patients, eight achieved a partial response, and 11 had stable disease, yielding an objective response rate of 36.4% (95% CI: 17.2–59.3%) and a disease control rate of 86.4% (95% CI: 65.1–97.1%), with tumor shrinkage in 86.4% of patients. At a median follow-up of 9.9 months, the median progression-free survival was 6.6 months (95% CI: 4.8–12.4) with 6-month and 9-month PFS rates of 63.6% and 43.5%, respectively. Median overall survival was 12.5 months (95% CI: 7.8-not reached), with 62.9% of patients alive at 12 months. Furthermore, treatment was well tolerated, with no Grade 4/5 treatment-related adverse events. These findings are hypothesis-generating and warrant confirmation in adequately powered, randomized trials. ClinicalTrials.gov: NCT05947825.
- Open Access
- 13 October 2026
- Published by Springer Nature in Oncogenesis
ABE-mediated dual targeting of TOX and ARHGEF1 synergistically enhances antitumor activity of tumor-infiltrating lymphocytes in PDAC
- 13 October 2026
- Published by Springer Nature in Oncogenesis
Open AccessABE-mediated dual targeting of TOX and ARHGEF1 synergistically enhances antitumor activity of tumor-infiltrating lymphocytes in PDAC
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure1-24 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Fig.S1. Analysis of the number of positive LNs and the lymph node ratio (LNR, the ratio of positive to examined nodes) in PDAC patients; Fig.S2. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S3. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S4. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S5. Validation of SPiDER probe and the effects of dasatinib plus quercetin; Fig.S6. The gating strategy for senescent cells and the senescence levels in normal tissues, IPMN and PDAC; Fig.S7. The effects of specific deletion of p16 and p21 in CAFs; Fig.S8.The effects of conditional deletion of p16 and p21 in CAFs; Fig.S9. Clinical significance of senescent CAFs in PDAC; Fig.S10. The paracrine effects of malignant epithelial components on the induction of senescent CAFs; Fig.S11. The validation of senescent CAFs; Fig.S12. The glucose metabolism level in senescent CAFs; Fig.S13. The effects of LDHA inhibition in LNM; Fig.S14. The effects of specific deletion of PHGDH in lymphatic endothelia cells. Data related to Fig.4P-R; Fig.S15. The evaluation of different lactylated histones in CAFs; Fig.S16. The distance between CAFs and Tregs in human and mouse models. Data related to Figure 6; Fig.S17. SenCAFs-derived lactate activates transcription of CCL17 by enhancing histone lactylation in LECs; Fig.S18. The HDAC inhibitor chidamide selectively kills senCAFs in PDAC; Fig.S19. The HDAC inhibitor chidamide selectively kills senCAFs, increases the efficacy of pancreatic cancer standard of care and further suppresses LNM and distal metastasis in PDAC;Fig.S20. The HDAC inhibitor chidamide could sensitize PDAC to chemoimmunotherapy;Fig.S21. The tumor re-challenge assay for chidamide plus chemoimmunotherapy; Fig.S22. The effects of chidamide in Pdgfrα-cre-p16/cdkn1aΔ and WT mice;Fig.S23. The therapeutic effects of gemcitabine, nab-paclitaxel, chidamide and QL1706 in PDX models;Fig.S24. Schematic illustration for the project.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure1-24 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Fig.S1. Analysis of the number of positive LNs and the lymph node ratio (LNR, the ratio of positive to examined nodes) in PDAC patients; Fig.S2. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S3. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S4. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S5. Validation of SPiDER probe and the effects of dasatinib plus quercetin; Fig.S6. The gating strategy for senescent cells and the senescence levels in normal tissues, IPMN and PDAC; Fig.S7. The effects of specific deletion of p16 and p21 in CAFs; Fig.S8.The effects of conditional deletion of p16 and p21 in CAFs; Fig.S9. Clinical significance of senescent CAFs in PDAC; Fig.S10. The paracrine effects of malignant epithelial components on the induction of senescent CAFs; Fig.S11. The validation of senescent CAFs; Fig.S12. The glucose metabolism level in senescent CAFs; Fig.S13. The effects of LDHA inhibition in LNM; Fig.S14. The effects of specific deletion of PHGDH in lymphatic endothelia cells. Data related to Fig.4P-R; Fig.S15. The evaluation of different lactylated histones in CAFs; Fig.S16. The distance between CAFs and Tregs in human and mouse models. Data related to Figure 6; Fig.S17. SenCAFs-derived lactate activates transcription of CCL17 by enhancing histone lactylation in LECs; Fig.S18. The HDAC inhibitor chidamide selectively kills senCAFs in PDAC; Fig.S19. The HDAC inhibitor chidamide selectively kills senCAFs, increases the efficacy of pancreatic cancer standard of care and further suppresses LNM and distal metastasis in PDAC;Fig.S20. The HDAC inhibitor chidamide could sensitize PDAC to chemoimmunotherapy;Fig.S21. The tumor re-challenge assay for chidamide plus chemoimmunotherapy; Fig.S22. The effects of chidamide in Pdgfrα-cre-p16/cdkn1aΔ and WT mice;Fig.S23. The therapeutic effects of gemcitabine, nab-paclitaxel, chidamide and QL1706 in PDX models;Fig.S24. Schematic illustration for the project.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2-3 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 2 shows the patient characteristics in the proof-of-concept clinical trial; Supplementary Table 3 shows treatment-related adverse events in the proof-of-concept clinical trial.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2-3 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 2 shows the patient characteristics in the proof-of-concept clinical trial; Supplementary Table 3 shows treatment-related adverse events in the proof-of-concept clinical trial.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table1 shows the senescence genesets
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table1 shows the senescence genesets
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Detailed Supplementary Methods 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Detailed Supplementary Methods and Materials
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessDetailed Supplementary Methods 1 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Detailed Supplementary Methods and Materials
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 4 shows primers and probes used in experiments.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Supplementary Table 4 shows primers and probes used in experiments.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF23
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti–PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. Significance: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF23
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti–PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. Significance: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.
- Open Access
- 7 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy
Cytosine base editors (CBEs) mediate precise C-to-T conversion and hold considerable therapeutic promise, yet their editing function and utility in oncology remain underexplored. Here, we integrate evolutionary scale modeling (ESM) with structure-guided mutagenesis to remodel human APOBEC3F (A3F), yielding a panel of high-performance CBEs. Our high-efficiency A3F-CBEs achieve up to 1.9- and 3.3-fold higher on-target editing within the canonical editing window than A3A- and Anc689-BE4max, respectively. The high-accuracy A3F-CBEs deliver up to 3.0-fold improvement over haA3A-G at the majority of surveyed loci without compromising specificity. To demonstrate therapeutic potential, we deploy a dual-AAV platform packaging A3F-BE4max and dual gRNAs co-targeting KRAS and MYC in pancreatic ductal adenocarcinoma (PDAC) models. It elicits robust oncogene silencing and inhibited PDAC cell proliferation both in vitro and patient-derived organoids (PDOs). In a PDAC mouse model, it markedly suppresses tumor burden and extends survival. Our work establishes ESM-guided A3F-based CBEs as a versatile, precise platform for cancer genetic therapy.
- 7 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessRationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy
Cytosine base editors (CBEs) mediate precise C-to-T conversion and hold considerable therapeutic promise, yet their editing function and utility in oncology remain underexplored. Here, we integrate evolutionary scale modeling (ESM) with structure-guided mutagenesis to remodel human APOBEC3F (A3F), yielding a panel of high-performance CBEs. Our high-efficiency A3F-CBEs achieve up to 1.9- and 3.3-fold higher on-target editing within the canonical editing window than A3A- and Anc689-BE4max, respectively. The high-accuracy A3F-CBEs deliver up to 3.0-fold improvement over haA3A-G at the majority of surveyed loci without compromising specificity. To demonstrate therapeutic potential, we deploy a dual-AAV platform packaging A3F-BE4max and dual gRNAs co-targeting KRAS and MYC in pancreatic ductal adenocarcinoma (PDAC) models. It elicits robust oncogene silencing and inhibited PDAC cell proliferation both in vitro and patient-derived organoids (PDOs). In a PDAC mouse model, it markedly suppresses tumor burden and extends survival. Our work establishes ESM-guided A3F-based CBEs as a versatile, precise platform for cancer genetic therapy.
Trogocytosis-orchestrated CLDN18.2-“dressed” CD8 + T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade
Background: As it is a tumour-associated antigen in epithelial cells, research on claudin18.2 (CLDN18.2) has focused on its role as a therapeutic target in pancreatic cancers and its part in maintaining tight junctions. Objective: We elucidate the role of trogocytosis-related CLDN18.2 in CD8 + T cells and pancreatic ductal adenocarcinoma (PDAC) progression. Design: We constructed humanised hCD34 + , Trp53 R172H Kras G12D Pdx1-cre (KPC), Cldn18.2 knockout (KO), and patient-derived xenograft/organoid mouse models. Flow cytometry, immunofluorescence, single-cell RNA-sequencing and immunoprecipitation-mass spectrometry (IP-MS) were performed. Results: CLDN18.2 + CD8 + T cells indicated poor pancreatic cancer prognosis and immunotherapeutic resistance. CD8 + T cells acquired CLDN18.2 from tumour cells via trogocytosis, inhibiting their activation and cytotoxicity. “Dressed” CLDN18.2 suppressed glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 + T cells. Mechanically, trogocytosis-related CLDN18.2 induced GSK3β/CK1α-mediated β-catenin phosphorylation, promoting β-catenin ubiquitination and proteasome degradation in CD8 + T cells. CLDN18.2 interacted with β-catenin’s N-terminal domain via its C-terminal domain, further strengthening the interaction between β-catenin and CK1α. Moreover, CLDN18.2 + CD8 + T cells preferentially ‘homed’ to the bone marrow through the CXCL12/CXCR4 axis, skewed haematopoietic stem cell myeloid differentiation and induced systemic immune senescence via IL1α. Notably, preclinical mouse studies showed PC18.1 peptide sensitised immunotherapy and suppressed PDAC progression by disrupting the CLDN18.2/β-catenin interaction in CD8 + T cells. Conclusions: Trogocytosis-related CLDN18.2 inhibited the glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 + T cells by promoting the ubiquitin-proteasomal degradation of β-catenin in PDAC. Therefore, targeting trogocytosis-related CLDN18.2 + CD8 + T cells may be a promising therapeutic strategy to inhibit PDAC progression.
Trogocytosis-orchestrated CLDN18.2-“dressed” CD8 + T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade
Background: As it is a tumour-associated antigen in epithelial cells, research on claudin18.2 (CLDN18.2) has focused on its role as a therapeutic target in pancreatic cancers and its part in maintaining tight junctions. Objective: We elucidate the role of trogocytosis-related CLDN18.2 in CD8 + T cells and pancreatic ductal adenocarcinoma (PDAC) progression. Design: We constructed humanised hCD34 + , Trp53 R172H Kras G12D Pdx1-cre (KPC), Cldn18.2 knockout (KO), and patient-derived xenograft/organoid mouse models. Flow cytometry, immunofluorescence, single-cell RNA-sequencing and immunoprecipitation-mass spectrometry (IP-MS) were performed. Results: CLDN18.2 + CD8 + T cells indicated poor pancreatic cancer prognosis and immunotherapeutic resistance. CD8 + T cells acquired CLDN18.2 from tumour cells via trogocytosis, inhibiting their activation and cytotoxicity. “Dressed” CLDN18.2 suppressed glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 + T cells. Mechanically, trogocytosis-related CLDN18.2 induced GSK3β/CK1α-mediated β-catenin phosphorylation, promoting β-catenin ubiquitination and proteasome degradation in CD8 + T cells. CLDN18.2 interacted with β-catenin’s N-terminal domain via its C-terminal domain, further strengthening the interaction between β-catenin and CK1α. Moreover, CLDN18.2 + CD8 + T cells preferentially ‘homed’ to the bone marrow through the CXCL12/CXCR4 axis, skewed haematopoietic stem cell myeloid differentiation and induced systemic immune senescence via IL1α. Notably, preclinical mouse studies showed PC18.1 peptide sensitised immunotherapy and suppressed PDAC progression by disrupting the CLDN18.2/β-catenin interaction in CD8 + T cells. Conclusions: Trogocytosis-related CLDN18.2 inhibited the glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 + T cells by promoting the ubiquitin-proteasomal degradation of β-catenin in PDAC. Therefore, targeting trogocytosis-related CLDN18.2 + CD8 + T cells may be a promising therapeutic strategy to inhibit PDAC progression.